Browse by Clinical Topic:


Featured CME/CE Content:
 
neuroscienceCME Editors' Picks:



Chronic Hepatitis B Virus Infection: Advancing Care, Changing Lives

presurvey


Premiere Date: Wednesday, November 28, 2012

This activity offers CE credit for:

  1. Physicians (CME)
  2. Nurses (CNE)
  3. Pharmacists (ACPE)
  4. Other


All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™

Credit Expiration Date:
Wednesday, December 31, 2014
Note: Credit Is No Longer Available

Faculty


Kris V. Kowdley, MD, FACP, FACG, FASGE, AGAFKris V. Kowdley, MD, FACP, FACG, FASGE, AGAF (Moderator)
Director, Liver Care Network and Organ Care Research
Swedish Medical Center
Seattle, WA

Larry Culpepper, MD, MPHLarry Culpepper, MD, MPH 
Professor of Family Medicine
Boston University School of Medicine
Staff Physician, Family Medicine
Boston Medical Center
Boston, MA

Helen S. Te, MD, AGAFHelen S. Te, MD, AGAF 
Associate Professor of Medicine
Medical Director
Adult Liver Transplant Program
University of Chicago Medicine
Chicago, IL

Su Wang, MD, MPH, FACPSu Wang, MD, MPH, FACP 
Medical Director, Viral Hepatitis Programs and Center for Asian Health
Cooperman Barnabas Medical Center, RJWBarnabas Health
Livingston, NJ

Statement of Need

Public health surveillance and immunization have greatly reduced infection with hepatitis B virus (HBV). Still, chronic HBV infection constitutes a public health problem and many clinical gaps exist in the delivery of preventive and therapeutic services to adults who are chronically infected with HBV. A 2010 Institute of Medicine (IOM) report entitled Hepatitis and Liver Cancer: Information for Health Care Providers outlines recommendations to address these gaps and improve the lives of at-risk patients. The IOM recommendations center on increased screening of at-risk adults, improved patient education about the meaning of HBV serologic results, and enhanced efforts to both improve patient access to treatment and monitoring services and maintain patient adherence to a follow-up routine, whether through primary care or specialty referral.

This CME Outfitters Live and On Demand features national expert faculty sharing best practices for primary care management of HBV infection within the framework of American Association for the Study of Liver Diseases guidelines, emerging data, and expert experience and thought. This activity is the flagship educational experience in the CME Outfitters vWorld™ virtual learning environment, which offers online gaming, improved peer interaction, a resource library, and more.


  • Institute of Medicine. Hepatitis and Liver Cancer: A National Strategy for Prevention and Control of Hepatitis B and C. Washington DC: National Academies Press; 2011. http://books.nap.edu/openbook.php?record_id=12793. Accessed August 7, 2012.
  • Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology. 2009;50(3):661-662. PMID: 19714720.


Additional Education on Hepatitis B:
  • Best Primary Care Practices for Hepatitis B Infection: Focus on Screening and Diagnosis
    For information and to register Click Here
  • Best Primary Care Practices for Hepatitis B Infection: Focus on Therapeutic Strategy Planning and Treatment Counseling
    For information and to register Click Here
  • Activity Goal

    To educate primary care clinicians, in accordance with guidelines, on using effective screening, diagnostics, patient education, and general management strategies for adults who have or who are at risk of developing chronic viral hepatitis due to hepatitis B virus.

    Learning Objectives

    At the end of this CE activity, participants should be able to:

    • Increase the rate at which health care providers screen at-risk patients for hepatitis B infection.
    • Provide accurate patient education and counseling to HBsAg-positive patients about the significance of their serologic findings and use of the findings to guide next treatment steps for hepatitis B infection.
    • Devise a plan or refer for ongoing monitoring, follow-up, and determination of treatment candidacy for hepatitis B.

    The following learning objectives pertain only to those requesting CNE or CPE credit:

    • Identify, in accordance with CDC guidelines, at-risk patients who should be screened for hepatitis B infection.
    • Correlate serologic patterns with the patient’s stage of hepatitis B disease and need for treatment in HBsAG-positive patients.
    • Help set patient expectations about the need for monitoring, follow-up, and determination of treatment candidacy for patients with chronic HBV infection.

    Financial Support

    Supported by educational grants from Bristol-Myers Squibb and Gilead Sciences, Inc.

    Target Audience

    Physicians, physician assistants, nurses, nurse practitioners, pharmacists, and other health care professionals whose scope of practice involves providing primary care for adults who have or who are at risk of developing chronic viral hepatitis.

    Credit Information

    CME Credit (Physicians):
    CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME Outfitters, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    AAFP Credit (Family Physicians):
    The enduring material activity, Chronic Hepatitis B Virus Infection: Advancing Care, Changing Lives, has been reviewed and is accepted for up to 1.5 Prescribed credit(s) by the American Academy of Family Physicians. AAFP certification begins November 28, 2012. Term of approval is for one year from this date with the option of yearly renewal. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    CNE Credit (Nurses):
    Provider approved by the California Board of Registered Nursing, Provider Number CEP 15510, for 1.5 contact hours

    CPE Credit (Pharmacists):
    ACPE CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 1.5 contact hours (0.15 CEUs)
    Universal Activity Number:
    0376-0000-12-017-H01-P
    Activity Type: knowledge-based

    Post-tests, credit request forms, and activity evaluations must be completed online at www.cmeoutfitters.com/TST707 (requires free account activation), and participants can print their certificate or statement of credit immediately (80% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit www.neurosciencecme.com/technical.asp.

    Disclosure Declaration

    It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CME/CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CME/CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

    Dr. Kowdley has disclosed that he has received research grants from Abbott Laboratories; Beckman Coulter, Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Conatus Pharmaceuticals, Inc.; Gilead; Ikaria, Inc.; Intercept Pharmaceuticals, Inc.; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; Mochida Pharmaceuticals, Inc.; Vertex Pharmaceuticals Incorporated. He serves as a consultant to/is on the advisory boards of Abbott Laboratories; Gilead; Merck & Co., Inc.; Novartis Corporation and Vertex Pharmaceuticals Incorporated.

    Dr. Culpepper has disclosed that he serves as a consultant to AstraZeneca Pharmaceuticals LP; Forest Laboratories Inc.; Janssen Pharmaceuticals, Inc.; Lunbeck; Merck & Co., Inc; Pfizer Inc; and Takeda Pharmaceuticals USA, Inc. Dr. Culpepper serves on the speakers bureau for Merck & Co., Inc.

    Dr. Te has no disclosures to report.

    Dr. Wang has disclosed that she serves as a consultant to Gilead Sciences, Inc.

    Jeffrey Helfand, DO, MS (content/peer reviewer) has no disclosures to report.

    Ruth Cody, BSN, RN-BC (content/peer reviewer) has no disclosures to report.

    Nancy Jennings, MSN, MBA, MHA, RNC (content/peer reviewer) has no disclosures to report.

    Monique Johnson, MD, CCMEP (planning committee) has no disclosures to report.

    Joy Bartnett Leffler, MLA, NASW, CSE (planning committee) has no disclosures to report.

    Sandra Haas Binford, MAEd (planning committee) has no disclosures to report.

    Sharon Tordoff, CCMEP (planning committee) has no disclosures to report.

    Unlabeled Use Disclosure

    Faculty of this CME/CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

    CME Outfitters, LLC, the faculty, Bristol-Myers Squibb, and Gilead Sciences, Inc. do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.

    Questions about this activity? Call us at 877.CME.PROS (877.263.7767).

    TV-077-112812-90

    Home      |      Register/Log In      |      Activities      |      Communities of Practice      |      About      |      Download